ClinicalTrials.gg
CompletedNCT00333840Updated Oct 14, 2013Results posted

Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

A Phase 3 interventional study of imatinib mesilate and interferon-alpha (INF-a) in Chronic Myelogenous Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 163 sites in 16 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-10-14.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,106
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 1 open to participants now, 5 under way, none of them phase 3. imatinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
2nd of 83
1,106 · median 60
Started
2000
with 5 others
Phase 3
14 of 93
none open now
Registered
45th of 93
by date
Lead sponsor
15 of 93
Novartis Pharmaceuticals

Among the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 2nd largest by enrollment of the 83 interventional ones that give a count, is one of 6 that started in 2000, is one of 14 in phase 3, and was the 45th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

1 of the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About imatinib

imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate and compare the side effects and anti-leukemic benefits of imatinib with those of interferon and Ara-C for patients who have chronic myeloid leukemia (CML) in the chronic phase. Patients in this study will be randomized (1:1) to receive either interferon plus Ara-C or imatinib as initial treatment.

03

Conditions studied

  • Chronic Myelogenous Leukemia

Keywords

  • CML
  • STI571
  • imatinib
  • interferon
  • interferon alpha
  • cytosine arabinoside
  • chronic myeloid leukemia
  • Philadelphia chromosome positive
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have signed consent for Amendment 5
  • Must have completed visit 62 of the core IRIS trial or be in follow-up
  • Must be on STI571 treatment
  • If on IFN treatment, must be willing to cross over to STI571 treatment

Exclusion criteria

Exclusion criteria:

  • Patients who have discontinued from the study and are in follow-up
  • Patients who are on IFN treatment and do not want to cross over to STI571 treatment
  • Patients who have not consented to amendment 5
  • Patients who did not complete the amendment 5 protocol

Additional protocol-defined inclusion/exclusion criteria may apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
1,106 participants (actual)

Study arms

  • Experimental
    imatinib (STI571)

    In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10\^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m\^2/day (max 40 mg) SC injection for 10 days every month. Maximum study duration was 11.5 years.

    Drug: imatinib mesilate · Drug: interferon-alpha (INF-a) · Drug: cytarabine (ARA-C)

  • Active comparator
    IFN-a+Ara-C

    In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m\^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10\^9/liter. If protocol specific criteria applied, participants were eligible to crossover to the second-line treatment period to receive imatinib (STI571). IFN treatment was discontinued with protocol amendment 6. Maximum study duration was 8 years.

    Drug: imatinib mesilate · Drug: interferon-alpha (INF-a) · Drug: cytarabine (ARA-C)

Interventions

  • imatinib supplied as 100 mg and 400 mg tablets or 100 mg capsules.

    Also known as: Glivec®, Gleevec®, STI571

  • interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day.

    Also known as: Roferon®-A, Intron®-A

  • cytarabine 20 mg/m\^2/day (max 40 mg) SC for 10 days every month.

06

What researchers measure

Primary outcomes

  1. Kaplan-Meier Estimates of Overall Survival (All Randomized Participants)

    Overall survival was defined as the time between date of randomization and death due to any cause. The time was censored at last examination date for patients who were still being treated and at date of last contact for patients who discontinued treatment. Kaplan-Meier estimates of the percentage of participants at each time point was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.

    Time frame: 12,24,36,48,60,72,84,96,108,120,132 and 144 months

Secondary outcomes

  1. Kaplan Meier Estimates of Event Free Survival (All Randomized Participants)

    Event-free survival is defined as the time between randomization and the earliest of any of the following events on treatment: * progression to Accelerated Phase (AP) or Blast Crisis (BC) * loss of Complete Hematological Response (CHR) * loss of Major Cytogenetic Response (MCyR) confirmed * loss of Major Cytogenetic Response (MCyR) unconfirmed * increase in white blood cell count (WBC) if approved by the Study Management Committee (SMC) * death (due to any cause when reported as primary reason for discontinuation of treatment). Kaplan Meier estimates of the percentage of participants with Event Free Survival at the given time point was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.

    Time frame: 12,24,36,48,60,72,84,96,108,120,132 and 144 months

  2. Percentage of Participants With Event Free Survival Events (All Randomized Participants)

    Event-free survival is defined as the time between randomization and the earliest of any of the following events on treatment: * progression to Accelerated Phase (AP) or Blast Crisis (BC) * loss of Complete Hematological Response (CHR) * loss of Major Cytogenic Response (MCyR) confirmed * loss of Major Cytogenic Response (MCyR) unconfirmed * increase in white blood cell count (WBC) if approved by the Study Management Committee (SMC) * death (due to any cause when reported as primary reason for discontinuation of treatment). The percentage of participants with Event Free Survival events in each category was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.

    Time frame: 144 months

  3. Kaplan Meier Estimates of Time to Progression to Accelerated Phase (AP) or Blast Crisis (BC) (All Randomized Participants)

    Time to progression to AP/BC is defined as the time between randomization and either of the following events on treatment: death (due to CML when reported as primary reason for discontinuation of treatment) or progression to Accelerated Phase or Blast Crisis and is censored at last examination date for patients without event. No data after discontinuation of study treatment was included. The Kaplan Meier estimates of the percentage of participants with survival without progression to AP/BC at the given time point was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.

    Time frame: 12,24,36,48,60,72,84,96,108,120,132 and 144 months

  4. Percentage of Participants With Best Cytogenetic Response (First-line Treatment)

    Bone marrow aspirate was performed to evaluate cytogenetic results (percentage of Philadelphia chromosome positive (Ph+) metaphases) and amount of blasts and promyelocytes in bone marrow to establish cytogenetic response. Major Cytogenetic Response= Complete Response or Partial Response. Complete Cytogenetic Response= 0 % of Ph+ metaphases (out of 20 metaphases). Partial Cytogenetic Response= \> 0 and ≤ 35 % of Ph+ metaphases (out of 20 metaphases). The percentage of participants with cytogenetic response in each category was calculated.

    Time frame: 144 months

  5. Percentage of Participants With Best Cytogenetic Response (Second-line Treatment)

    Bone marrow aspirate was performed to evaluate cytogenetic results (percentage of Ph chromosome (Ph+) containing metaphases) and the amount of blasts and promyelocytes in bone marrow to establish cytogenetic response. Major Cytogenetic Response= Complete Response or Partial Response. Complete Cytogenetic Response= 0 % of Ph+ metaphases (out of 20 metaphases). Partial Cytogenetic Response= \> 0 and ≤ 35 % Ph+ metaphases (out of 20 metaphases). The percentage of participants with cytogenetic response in each category was calculated.

    Time frame: 144 months

  6. Number of Participants With Serious Adverse Events as a Measure of Safety (First-line Treatment)

    A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant

    Time frame: 144 months

  7. Number of Participants With Serious Adverse Events as a Measure of Safety (Second-line Treatment)

    A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant

    Time frame: 144 months

  8. Percentage of Participants With Major Molecular Response (First-line Treatment)

    Major Molecular Response was determined using a quantitative polymerase chain reaction (PCR) laboratory test and was defined as BCR-ABL protein transcripts of ≤ 0.1% according to the international scale.

    Time frame: 12,24,36,48,60,72,84,96,108,120,132 and 144 months

  9. Percentage of Participants With Major Molecular Response (Second-line Treatment)

    Major Molecular Response was determined using a quantitative polymerase chain reaction (PCR) laboratory test and was defined as BCR-ABL protein transcripts of ≤ 0.1% according to the international scale.

    Time frame: 12,24,36,48,60,72,84,96,108,120,132 and 144 months

07

Results

Posted Oct 14, 2013

Participant flow

First-line Treatment Period
Participant flow — First-line Treatment Period
MilestoneImatinib (STI571)IFN-a + Ara-CImatinib to IFN-a + Ara-CIFN-a + Ara-C to Imatinib
Started55355300
Safety population; received study drug55153300
Completed267700
Not completed28654600
Withdrew: Adverse event383700
Withdrew: Abnormal laboratory values3100
Withdrew: Abnormal procedure2000
Withdrew: Unsatisfactory therapeutic effect882900
Withdrew: No longer required study drug21800
Withdrew: Protocol violation171700
Withdrew: Subject withdrew consent577700
Withdrew: Lost to follow-up15600
Withdrew: Administrative problems12600
Withdrew: Death19200
Withdrew: Crossed over to other treatment arm1436300
Second-line Treatment Period
Participant flow — Second-line Treatment Period
MilestoneImatinib (STI571)IFN-a + Ara-CImatinib to IFN-a + Ara-CIFN-a + Ara-C to Imatinib
Started0014363
Completed000175
Not completed0014188
Withdrew: Adverse event00334
Withdrew: Abnormal laboratory values0003
Withdrew: Abnormal procedure0001
Withdrew: Unsatisfactory therapeutic effect00970
Withdrew: No longer required study drug00114
Withdrew: Protocol violation00110
Withdrew: Subject withdrew consent00034
Withdrew: Lost to follow-up0006
Withdrew: Administrative problems0007
Withdrew: Death0009

Outcome measures

PrimaryKaplan-Meier Estimates of Overall Survival (All Randomized Participants)

Overall survival was defined as the time between date of randomization and death due to any cause. The time was censored at last examination date for patients who were still being treated and at date of last contact for patients who discontinued treatment. Kaplan-Meier estimates of the percentage of participants at each time point was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.

Time frame:
12,24,36,48,60,72,84,96,108,120,132 and 144 months
Reported as:
Number · Percentage of participants
Kaplan-Meier Estimates of Overall Survival (All Randomized Participants)
Percentage of participantsImatinib (STI571)IFN-a + Ara-C
12 months (n = 553, 553)98.9 (98 to 100)97.7 (96 to 99)
24 months (n = 542, 512)96.093.6
36 months (n = 518, 471)92.489.8
48 months (n = 492, 441)90.487.7
60 months (n = 475, 411)89.485.4
72 months (n = 461, 388)88.283.8
84 months (n = 446, 373)86.683.1
96 months (n = 430, 358)85.481.4
108 months (n = 391, 315)84.379.9
120 months (n = 368, 299)83.378.8
132 months (n = 356, 288)82.877.7
144 months (n = 250, 199)81.375.4
SecondaryKaplan Meier Estimates of Event Free Survival (All Randomized Participants)

Event-free survival is defined as the time between randomization and the earliest of any of the following events on treatment: * progression to Accelerated Phase (AP) or Blast Crisis (BC) * loss of Complete Hematological Response (CHR) * loss of Major Cytogenetic Response (MCyR) confirmed * loss of Major Cytogenetic Response (MCyR) unconfirmed * increase in white blood cell count (WBC) if approved by the Study Management Committee (SMC) * death (due to any cause when reported as primary reason for discontinuation of treatment). Kaplan Meier estimates of the percentage of participants with Event Free Survival at the given time point was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.

Time frame:
12,24,36,48,60,72,84,96,108,120,132 and 144 months
Reported as:
Number · Percentage of participants
Kaplan Meier Estimates of Event Free Survival (All Randomized Participants)
Percentage of participantsImatinib (STI571)IFN-a + Ara-C
12 months (n = 553, 553)96.679.4
24 months (n = 505, 332)89.670.0
36 months (n = 448, 263)85.367.0
48 months (n = 415, 241)83.963.7
60 months (n = 395, 223)83.261.9
72 months (n = 376, 207)83.060.1
84 months (n = 352, 181)82.059.0
96 months (n = 334, 166)81.058.3
108 months (n = 301, 141)79.956.6
120 months (n = 269, 130)79.656.6
132 months (n = 257, 124)79.656.6
144 months (n = 143, 76)79.651.8
SecondaryPercentage of Participants With Event Free Survival Events (All Randomized Participants)

Event-free survival is defined as the time between randomization and the earliest of any of the following events on treatment: * progression to Accelerated Phase (AP) or Blast Crisis (BC) * loss of Complete Hematological Response (CHR) * loss of Major Cytogenic Response (MCyR) confirmed * loss of Major Cytogenic Response (MCyR) unconfirmed * increase in white blood cell count (WBC) if approved by the Study Management Committee (SMC) * death (due to any cause when reported as primary reason for discontinuation of treatment). The percentage of participants with Event Free Survival events in each category was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.

Time frame:
144 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Event Free Survival Events (All Randomized Participants)
Percentage of participantsImatinib (STI571)IFN-a + Ara-C
Participants with events17.932.2
Progression to AP or BC6.912.8
Loss of CHR2.77.6
Loss of MCyR (confirmed)4.25.4
Loss of MCyR (unconfirmed)0.91.1
Increase of WBC0.23.4
Death3.11.8
SecondaryKaplan Meier Estimates of Time to Progression to Accelerated Phase (AP) or Blast Crisis (BC) (All Randomized Participants)

Time to progression to AP/BC is defined as the time between randomization and either of the following events on treatment: death (due to CML when reported as primary reason for discontinuation of treatment) or progression to Accelerated Phase or Blast Crisis and is censored at last examination date for patients without event. No data after discontinuation of study treatment was included. The Kaplan Meier estimates of the percentage of participants with survival without progression to AP/BC at the given time point was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.

Time frame:
12,24,36,48,60,72,84,96,108,120,132 and 144 months
Reported as:
Number · Percentage of participants
Kaplan Meier Estimates of Time to Progression to Accelerated Phase (AP) or Blast Crisis (BC) (All Randomized Participants)
Percentage of participantsImatinib (STI571)IFN-a + Ara-C
12 months (n = 553, 553)98.592.9
24 months (n = 513, 388)95.790.0
36 months (n = 461, 337)94.087.9
48 months (n = 431, 311)93.184.7
60 months (n = 409, 289 )92.783.5
72 months (n = 384, 265)92.783.1
84 months (n = 358, 236)92.782.4
96 months (n = 338, 220)92.482.4
108 months (n = 305, 189)92.182.4
120 months (n = 272, 175)92.182.4
132 months (n = 259, 165)92.182.4
144 months (n = 145, 94)92.182.4
SecondaryPercentage of Participants With Best Cytogenetic Response (First-line Treatment)

Bone marrow aspirate was performed to evaluate cytogenetic results (percentage of Philadelphia chromosome positive (Ph+) metaphases) and amount of blasts and promyelocytes in bone marrow to establish cytogenetic response. Major Cytogenetic Response= Complete Response or Partial Response. Complete Cytogenetic Response= 0 % of Ph+ metaphases (out of 20 metaphases). Partial Cytogenetic Response= \> 0 and ≤ 35 % of Ph+ metaphases (out of 20 metaphases). The percentage of participants with cytogenetic response in each category was calculated.

Time frame:
144 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Best Cytogenetic Response (First-line Treatment)
Percentage of participantsImatinib (STI571)IFN-a + Ara-C
Major Cytogenic Response89.023.3
Complete Cytogenic Response82.811.6
Partial Cytogenic Response6.111.8
SecondaryPercentage of Participants With Best Cytogenetic Response (Second-line Treatment)

Bone marrow aspirate was performed to evaluate cytogenetic results (percentage of Ph chromosome (Ph+) containing metaphases) and the amount of blasts and promyelocytes in bone marrow to establish cytogenetic response. Major Cytogenetic Response= Complete Response or Partial Response. Complete Cytogenetic Response= 0 % of Ph+ metaphases (out of 20 metaphases). Partial Cytogenetic Response= \> 0 and ≤ 35 % Ph+ metaphases (out of 20 metaphases). The percentage of participants with cytogenetic response in each category was calculated.

Time frame:
144 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Best Cytogenetic Response (Second-line Treatment)
Percentage of participantsImatinib to IFN-a + Ara-CIFN-a + Ara-C to Imatinib
Major Cytogenic Response14.386.0
Complete Cytogenic Response7.181.0
Partial Cytogenic Response7.15.0
SecondaryNumber of Participants With Serious Adverse Events as a Measure of Safety (First-line Treatment)

A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant

Time frame:
144 months
Reported as:
Number · Participants
Number of Participants With Serious Adverse Events as a Measure of Safety (First-line Treatment)
ParticipantsImatinib (STI571)IFN-a + Ara-C
Number of Participants With Serious Adverse Events as a Measure of Safety (First-line Treatment)226163
SecondaryNumber of Participants With Serious Adverse Events as a Measure of Safety (Second-line Treatment)

A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant

Time frame:
144 months
Reported as:
Number · Participants
Number of Participants With Serious Adverse Events as a Measure of Safety (Second-line Treatment)
ParticipantsImatinib to IFN-a + Ara-CIFN-a + Ara-C to Imatinib
Number of Participants With Serious Adverse Events as a Measure of Safety (Second-line Treatment)2160
SecondaryPercentage of Participants With Major Molecular Response (First-line Treatment)

Major Molecular Response was determined using a quantitative polymerase chain reaction (PCR) laboratory test and was defined as BCR-ABL protein transcripts of ≤ 0.1% according to the international scale.

Time frame:
12,24,36,48,60,72,84,96,108,120,132 and 144 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Major Molecular Response (First-line Treatment)
Percentage of participantsImatinib (STI571)IFN-a + Ara-C
12 months (n= 305, 83)50.29.6
24 months (n= 102, 12)69.625.0
36 months (n= 68, 7)76.528.6
48 months (n= 305, 12)77.058.3
60 months (n= 316, 10)88.0100.0
72 months (n= 292, 9)88.088.9
84 months (n= 247, 8)91.987.5
96 months (n= 228, 4)92.5100.0
108 months (n= 233, 0)93.6NA
120 months (n= 204, 0)93.1NA
132 months (n= 168, 0)92.3NA
144 months (n= 1, 0)100.0NA
SecondaryPercentage of Participants With Major Molecular Response (Second-line Treatment)

Major Molecular Response was determined using a quantitative polymerase chain reaction (PCR) laboratory test and was defined as BCR-ABL protein transcripts of ≤ 0.1% according to the international scale.

Time frame:
12,24,36,48,60,72,84,96,108,120,132 and 144 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Major Molecular Response (Second-line Treatment)
Percentage of participantsIFN-a + Ara-C to Imatinib
12 months (n = 86)51.2
24 months (n = 62)69.4
36 months (n = 130)78.5
48 months (n = 216)81.9
60 months (n = 174)86.2
72 months (n = 146)91.1
84 months (n = 139)86.3
96 months (n = 138)87.0
108 months (n = 120)90.0
120 months (n = 84)85.7
132 months (n = 31)90.3
144 monthsNA

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Imatinib (STI571)—226/551 (41%)541/551 (98.2%)
IFN-a + Ara-C—163/533 (30.6%)531/533 (99.6%)
Imatinib to IFN-a + Ara-C—2/14 (14.3%)13/14 (92.9%)
IFN-a + Ara-C to Imatinib—160/363 (44.1%)347/363 (95.6%)
Most frequent serious events
Showing 10 of 674
Most frequent serious events
EventImatinib (STI571)IFN-a + Ara-CImatinib to IFN-a + Ara-CIFN-a + Ara-C to Imatinib
FatigueGeneral disorders3/5517/5331/143/363
PyrexiaGeneral disorders19/55120/5331/1412/363
ArthralgiaMusculoskeletal and connective tissue disorders4/55111/5331/142/363
Bone painMusculoskeletal and connective tissue disorders2/5516/5331/142/363
Neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/5512/5331/143/363
DizzinessNervous system disorders7/5515/5331/140/363
PneumoniaInfections and infestations12/5517/5330/1414/363
Blast crisis in myelogenous leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/5515/5330/1412/363
DepressionPsychiatric disorders2/55115/5330/142/363
Chest painGeneral disorders14/5514/5330/147/363
Most frequent other events
Showing 10 of 127
Most frequent other events
EventImatinib (STI571)IFN-a + Ara-CImatinib to IFN-a + Ara-CIFN-a + Ara-C to Imatinib
FatigueGeneral disorders214/551354/5337/14104/363
NauseaGastrointestinal disorders276/551325/5334/14138/363
Muscle spasmsMusculoskeletal and connective tissue disorders272/55163/5331/14168/363
DiarrhoeaGastrointestinal disorders250/551231/5332/14148/363
HeadacheNervous system disorders205/551231/5332/1487/363
PyrexiaGeneral disorders91/551217/5333/1442/363
Decreased appetiteMetabolism and nutrition disorders53/551207/5332/1418/363
MyalgiaMusculoskeletal and connective tissue disorders131/551200/5334/1463/363
ArthralgiaMusculoskeletal and connective tissue disorders173/551199/5333/1493/363
DepressionPsychiatric disorders84/551186/5333/1431/363

Baseline characteristics

Age Continuous
Age Continuous(years)Imatinib (STI571)IFN-a + Ara-CTotal
Median50.0 (18 to 70)51.0 (18 to 70)51.0 (18 to 70)
Sex: Female, Male
Sex: Female, Male(Participants)Imatinib (STI571)IFN-a + Ara-CTotal
Female211243454
Male342310652
08

Study locations

163 sites
  • Novartis Investigative Site
    Birmingham, Alabama 35294, United States
  • Novartis Investigative Site
    Montgomery, Alabama 36106, United States
  • Novartis Investigative Site
    Tucson, Arizona 85724, United States
  • Novartis Investigative Site
    Berkeley, California 94704, United States
  • Novartis Investigative Site
    Campbell, California 95008, United States
  • Novartis Investigative Site
    Duarte, California 91010, United States
  • Novartis Investigative Site
    La Jolla, California 92093-0960, United States
  • Novartis Investigative Site
    Denver, Colorado 80218, United States
  • Novartis Investigative Site
    Miami, Florida 33176-2197, United States
  • Novartis Investigative Site
    Orlando, Florida 32804, United States
  • Novartis Investigative Site
    Atlanta, Georgia 30342, United States
  • Novartis Investigative Site
    Honolulu, Hawaii 96813, United States
  • Novartis Investigative Site
    Chicago, Illinois 60611, United States
  • Novartis Investigative Site
    Chicago, Illinois 60612, United States
  • Novartis Investigative Site
    Chicago, Illinois 60637, United States
  • Novartis Investigative Site
    Decatur, Illinois 62526, United States
  • Novartis Investigative Site
    Beech Grove, Indiana 46107, United States
  • Novartis Investigative Site
    Witchita, Kansas 67214, United States
  • Novartis Investigative Site
    Louisville, Kentucky 40202, United States
  • Novartis Investigative Site
    New Orleans, Louisiana 70112, United States
  • Novartis Investigative Site
    Baltimore, Maryland 21201, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02115, United States
  • Novartis Investigative Site
    Worcester, Massachusetts 01665, United States
  • Novartis Investigative Site
    Ann Arbor, Michigan 48109, United States
  • Novartis Investigative Site
    Detroit, Michigan 48202-2689, United States
  • Novartis Investigative Site
    East Lansing, Michigan 48910, United States
  • Novartis Investigative Site
    Minneapolis, Minnesota 55455, United States
  • Novartis Investigative Site
    St. Louis, Missouri 63110, United States
  • Novartis Investigative Site
    Billings, Montana 59101, United States
  • Novartis Investigative Site
    Omaha, Nebraska 68198-7681, United States
  • Novartis Investigative Site
    Hackensack, New Jersey 07601, United States
  • Novartis Investigative Site
    Alburquerque, New Mexico 87109, United States
  • Novartis Investigative Site
    Alburquerque, New Mexico 87131, United States
  • Novartis Investigative Site
    Farmington, New Mexico 87131, United States
  • Novartis Investigative Site
    Buffalo, New York 14263, United States
  • Novartis Investigative Site
    New York, New York 10017, United States
  • Novartis Investigative Site
    New York, New York 10021, United States
  • Novartis Investigative Site
    New York, New York 10029, United States
  • Novartis Investigative Site
    Syracuse, New York 13210, United States
  • Novartis Investigative Site
    Chapel Hill, North Carolina 27599, United States
  • Novartis Investigative Site
    Charlotte, North Carolina 28203, United States
  • Novartis Investigative Site
    Durham, North Carolina 27710, United States
  • Novartis Investigative Site
    Winston-Salem, North Carolina 27157, United States
  • Novartis Investigative Site
    Cleveland, Ohio 44195, United States
  • Novartis Investigative Site
    Columbus, Ohio 43210, United States
  • Novartis Investigative Site
    Columbus, Ohio 43215, United States
  • Novartis Investigative Site
    Dayton, Ohio 45429, United States
  • Novartis Investigative Site
    Tulsa, Oklahoma 74136, United States
  • Novartis Investigative Site
    Portland, Oregon 97239, United States
  • Novartis Investigative Site
    Pittsburg, Pennsylvania 15224, United States
  • Novartis Investigative Site
    Pittsburg, Pennsylvania 15232, United States
  • Novartis Investigative Site
    Providence, Rhode Island 02903, United States
  • Novartis Investigative Site
    Spartanburg, South Carolina 29303, United States
  • Novartis Investigative Site
    Memphis, Tennessee 38119, United States
  • Novartis Investigative Site
    Nashville, Tennessee 37203, United States
  • Novartis Investigative Site
    Nashville, Tennessee 37205, United States
  • Novartis Investigative Site
    Dallas, Texas 75235-9179, United States
  • Novartis Investigative Site
    Dallas, Texas 75246, United States
  • Novartis Investigative Site
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Salt Lake City, Utah 84112, United States
  • Novartis Investigative Site
    Seattle, Washington 98109-1024, United States
  • Novartis Investigative Site
    Milwaukee, Wisconsin 53215, United States
  • Novartis Investigative Site
    Adelaide, Australia
  • Novartis Investigative Site
    Brisbane, Australia
  • Novartis Investigative Site
    Darlinghurst, Australia
  • Novartis Investigative Site
    East Melbourne, Australia
  • Novartis Investigative Site
    Nedlands, Australia
  • Novartis Investigative Site
    Parkville, Australia
  • Novartis Investigative Site
    Prahan, Australia
  • Novartis Investigative Site
    South Brisbane, Australia
  • Novartis Investigative Site
    St. Leonards, Australia
  • Novartis Investigative Site
    Sydney, 2050, Australia
  • Novartis Investigative Site
    Westmead, Australia
  • Novartis Investigative Site
    Wien, 1090, Austria
  • Novartis Investigative Site
    Bruxelles, 1000, Belgium
  • Novartis Investigative Site
    Bruxelles, 1200, Belgium
  • Novartis Investigative Site
    Godinne, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Calgary, Alberta T2N 4N2, Canada
  • Novartis Investigative Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Novartis Investigative Site
    Winnipeg, Manitoba R3E 0V9, Canada
  • Novartis Investigative Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Novartis Investigative Site
    Hamilton, Ontario L8N 3Z5, Canada
  • Novartis Investigative Site
    London, Ontario N6A 4G5, Canada
  • Novartis Investigative Site
    Ottawa, Ontario K1H 8L6, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Montreal, Quebec H1T 2M4, Canada
  • Novartis Investigative Site
    Montreal, Quebec H3A 1A1, Canada
  • Novartis Investigative Site
    Arhus, 8000, Denmark
  • Novartis Investigative Site
    Copenhagen, Denmark
  • Novartis Investigative Site
    Herlev, 2730, Denmark
  • Novartis Investigative Site
    Creteil, 94010, France
  • Novartis Investigative Site
    Lille, 59037, France
  • Novartis Investigative Site
    Lyon, 69437, France
  • Novartis Investigative Site
    Marseille, 13273, France
  • Novartis Investigative Site
    Nantes, 44035, France
  • Novartis Investigative Site
    Paris, 75475, France
  • Novartis Investigative Site
    Pessac, 33604, France
  • Novartis Investigative Site
    Poitiers, France

Showing the first 100 of 163 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324. PubMed 28273028 ↗
  • Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintas-Cardama A, Cortes J. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013 Jun 13;121(24):4867-74. doi: 10.1182/blood-2013-03-490128. Epub 2013 Apr 25. PubMed 23620574 ↗
  • Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y; IRIS (International Randomized Interferon vs STI571) Study Group. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008 Apr 15;111(8):4022-8. doi: 10.1182/blood-2007-10-116475. Epub 2008 Feb 6. PubMed 18256322 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2000, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2006
First posted
Jun 6, 2006
Start
Jun 2000
Primary completionActual
Mar 2012
CompletionActual
Mar 2012
Results first posted
Oct 14, 2013
Last update
Oct 14, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00333840
Responsible party
Sponsor
First posted
Jun 6, 2006
Start date
Jun 2000
Primary completion
Mar 2012
Completion
Mar 2012
Results posted
Oct 14, 2013
Last update
Oct 14, 2013

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Imatinib · Cytarabine

Start the discussion